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Abstract
Background:  Tumor recurrence following radical cystectomy for a low-grade superficial
transitional cell carcinoma (TCC) is exceedingly uncommon and has not been reported previously.
Case presentation: We describe a case of a young male presenting with anorexia, weight loss
and a large, painful locally destructive pelvic recurrence, ten years after radical cystoprostatectomy.
The pathology was consistent with a low-grade urothelial carcinoma. After an unsuccessful
treatment with cisplatin-based chemotherapy, the patient underwent a curative intent
hemipelvectomy with complete excision of tumor and is disease free at one year follow-up.
Conclusion: A literature review related to this unusual presentation is reported and a surgical
solutions over chemotherapy and radiotherapy is proposed.
Background
Low-grade papillary (Ta) urothelial carcinomas have the
lowest risk of progression to invasive disease and death of
all the superficial tumor types, with 50–70% recurrence
rate after transurethral resection of bladder tumor
(TURBT) and progression to invasive disease in 2.4–3.3%
of cases [1]. In comparison, the high-grade disease man-
aged with TURBT alone recurs in 80% of cases and
becomes invasive in 50% [2]. We describe an unusual case
of an aggressive low-grade papillary urothelial carcinoma
recurrence ten years following radical cystectomy.
Case presentation
A 48 year old male with a long history of smoking pre-
sented with weight loss, anorexia and pelvic pain. He had
a significant past history of a radical cystectomy ten years
prior for a large multi-focal non-invasive, low-grade pap-
illary (Ta) transitional cell carcinoma. The stated indica-
tions for cystectomy were large size of the mass and the
anticipated inability to perform a complete resection. The
pathological specimen which was reviewed at our institu-
tion was described as a low-grade non invasive papillary
multifocal transitional cell carcinoma (TCC). The margins
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were clear and fourteen uninvolved lymph nodes were
submitted. Postoperatively the patient recovered well and
was under surveillance without any disease till above
mentioned complaint. The patient's past history was also
significant for a straddle injury requiring open surgical
repair that occurred approximately 2 years prior to the
diagnosis of bladder cancer.
Physical examination revealed a thin uncomfortable male
with no other abnormal findings. Basic laboratory inves-
tigations were within normal limits. Imaging studies with
CT scan of abdomen and pelvis revealed a right sided large
heterogeneous pelvic mass with an area of central necrosis
and evidence of bone destruction (right acetabular inva-
sion) and distal rectal involvement (Figure 1). There was
no evidence of disease spread beyond this destructive pel-
vic mass.
A CT guided biopsy of this mass revealed a low-grade
urothelial carcinoma. Cisplatin based chemotherapy
along with growth factor support was administered [dose
dense methotrexate, vinblastine, doxorubicin and cispla-
tin (MVAC)]. After 3 uncomplicated cycles no tumor
response was achieved. It was then decided that a curative
intent en bloc resection represented the best option for
patient.
The patient underwent surgical resection of the mass
requiring a right hemipelvectomy, end colostomy and a
myocutaneous flap closure with penile and scrotal recon-
struction. The final pathology revealed an urothelial cell
tumor with predominantly low-grade morphologic fea-
tures, with focal areas of high grade tumor seen (Figure 2;
low magnification 10 × 10). The tumor invaded bone and
soft tissue in a broad-based pushing fashion. The tumor
formed nests with infiltration in the cortical bone, dissect-
ing the pelvic soft tissue. There was no lymphovascular
invasion and surgical margins were not involved. The
patient is free from disease recurrence after more than one
year following surgery.
Discussion
Risk factors for urothelial carcinoma recurrence after cys-
tectomy have been identified. Tumor grade (G), extent of
invasion (T) and lymph node involvement (N) are the
most widely recognized, beside others [3]. Herr et al., in a
multivariate analysis of 268 patients suggested that apart
from pathologic and nodal stage, number of lymph nodes
removed also influences the local recurrence and the dis-
ease specific survival [4]. Data regarding risks of recur-
rence is limited to intermediate and high-grade disease
and for the most part diseases that are considered inva-
sive, which highlight the rarity of the presented case. Five-
year survival for high-grade Ta disease following radical
cystectomy is between 88–100% [5]. The same statistics
for low-grade disease have not been reported, but is
expected to be far better.
Various site of metastasis such as skin, lung, orbit metatar-
sal bone, penis, posas muscle and calcaneum have been
reported in the literature in patients with superficial blad-
der cancer [6-9].
Saito reported a case of solitary subcutaneous scrotal
metastasis 18 months following initial treatment with
CT scan of pelvis showing a large locally destructive mass  lesion Figure 1
CT scan of pelvis showing a large locally destructive 
mass lesion. Showing a right sided large heterogeneous pel-
vic mass with an area of central necrosis with evidence of 
bone destruction (right acetabular invasion) and distal rectal 
involvement.
Low grade papillary urothelial carcinoma infiltrating pelvic  bone Figure 2
Low grade papillary urothelial carcinoma infiltrating 
pelvic bone. At low magnification (10 × 10) the low grade 
urothelial carcinoma forms nests and infiltrates cortical bone.World Journal of Surgical Oncology 2008, 6:103 http://www.wjso.com/content/6/1/103
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TURBT and intravesical instillation of Bacillus Calmette-
Guérin (BCG) with no tumor recurrence on repeat cystos-
copy. The histology of scrotal lesion was consistent with
the primary bladder tumor showing intermediate grade
transitional cell carcinoma (pT1a) disease [6].
Ku et al., reported a case of delayed recurrence 20 years fol-
lowing radical cystectomy for a low-grade muscle invasive
disease with skin and pelvic metastasis. The histology
from skin recurrence was consistent with well-differenti-
ated TCC. Subsequently patient developed a pelvic recur-
rence in spite of chemotherapy [10]. In our experience too
the patient failed to respond to the cisplatin based chem-
otherapy as reported in above mentioned study. Though,
this patient and our case had the same grade of disease,
interestingly, this patient had an invasive (pT2 N0 M0)
disease comparing to our case who had a non-invasive
(pTa N0 M0) disease.
Kumar  et al., reported a case of vaginal and omental
metastasis six years after TURBT for a well-differentiated
superficial TCC. Subsequent evaluation revealed no visi-
ble tumor in the bladder, but large omental deposit and
left obturator lymph node mass engulfing the ureter. The
report does not document the grade of recurrent TCC
[11].
Recently Dougherty et al. [12], reported two cases of lung
metastasis in patients with low-grade superficial bladder
cancer. Both patients presented with lung metastasis with
an underlying low-grade disease in bladder. Both patients
underwent metastatectomy, and platinum-based chemo-
therapy with a partial response. Neither patient under-
went a cystectomy for the primary disease [12].
There are many similarities of the above cases in the liter-
ature to our case. To our knowledge our case is the first
reported case of a non-invasive low grade urothelial carci-
noma treated with cystectomy with a late recurrence of the
same low-grade disease. The value of the cystectomy in
our case is high, because of the well known problem of
clinical understaging in urothelial carcinomas (Table 1).
The mechanism responsible for such a delayed presenta-
tion in our case is unknown. It is very likely that the tumor
was seeded in the pelvic area over 10 years prior, and con-
sidering the location of the tumor and its low-grade, it did
not become symptomatic for many years. The history of
saddle injury and/or the repair of this injury may have
played a role in this case. Traumatic implantation of the
cancer cell is supported by a report of similar implanta-
tion metastasis following laparoscopic bladder biopsy for
bladder cancer [13]. Thus a proposed possibility could be
linked to the precedent traumatic urethral injury with
local extravasation and possible implantation.
Modern cisplatin-based combination chemotherapy regi-
mens are associated with 40–60% objective response rates
in metastatic high-grade urothelial carcinomas. The regi-
men used in our case is associated with an overall
response rate of 62% [14]. Our intent was to shrink the
patient's tumor to enable a smaller surgery. The lack of
tumor response however is not surprising given the
tumor's low-grade and likely low mitotic rate.
Conclusion
We present an exceedingly rare occurrence of a pelvic
recurrence of a low-grade superficial TCC after cystec-
tomy. Delayed presentation with recurrent low-grade
urothelial carcinoma is an unusual entity and potential
mechanism of traumatic implantation should be consid-
ered. Characteristically low-grade tumor's are resistant to
systemic chemotherapy and curative-intent surgical resec-
tion of the tumor should be considered.
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